Wang Zhi-Quan, Zhang Rui, Zhang Peng-Pai, Liu Xiao-Hong, Sun Jian, Wang Jun, Feng Xiang-Fei, Lu Qiu-Fen, Li Yi-Gang
Department of Cardiology, Xinhua hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
J Cardiovasc Pharmacol. 2015 Apr;65(4):364-70. doi: 10.1097/FJC.0000000000000204.
Warfarin is yet the most widely used oral anticoagulant for thromboembolic diseases, despite the recently emerged novel anticoagulants. However, difficulty in maintaining stable dose within the therapeutic range and subsequent serious adverse effects markedly limited its use in clinical practice. Pharmacogenetics-based warfarin dosing algorithm is a recently emerged strategy to predict the initial and maintaining dose of warfarin. However, whether this algorithm is superior over conventional clinically guided dosing algorithm remains controversial. We made a comparison of pharmacogenetics-based versus clinically guided dosing algorithm by an updated meta-analysis. We searched OVID MEDLINE, EMBASE, and the Cochrane Library for relevant citations. The primary outcome was the percentage of time in therapeutic range. The secondary outcomes were time to stable therapeutic dose and the risks of adverse events including all-cause mortality, thromboembolic events, total bleedings, and major bleedings. Eleven randomized controlled trials with 2639 participants were included. Our pooled estimates indicated that pharmacogenetics-based dosing algorithm did not improve percentage of time in therapeutic range [weighted mean difference, 4.26; 95% confidence interval (CI), -0.50 to 9.01; P = 0.08], but it significantly shortened the time to stable therapeutic dose (weighted mean difference, -8.67; 95% CI, -11.86 to -5.49; P < 0.00001). Additionally, pharmacogenetics-based algorithm significantly reduced the risk of major bleedings (odds ratio, 0.48; 95% CI, 0.23 to 0.98; P = 0.04), but it did not reduce the risks of all-cause mortality, total bleedings, or thromboembolic events. Our results suggest that pharmacogenetics-based warfarin dosing algorithm significantly improves the efficiency of International Normalized Ratio correction and reduces the risk of major hemorrhage.
尽管近期出现了新型抗凝剂,但华法林仍是血栓栓塞性疾病中使用最广泛的口服抗凝剂。然而,在治疗范围内维持稳定剂量存在困难以及随之而来的严重不良反应显著限制了其在临床实践中的应用。基于药物遗传学的华法林给药算法是一种新近出现的预测华法林初始剂量和维持剂量的策略。然而,该算法是否优于传统的临床指导给药算法仍存在争议。我们通过更新的荟萃分析比较了基于药物遗传学的给药算法与临床指导给药算法。我们在OVID MEDLINE、EMBASE和Cochrane图书馆中搜索相关文献。主要结局是处于治疗范围内的时间百分比。次要结局是达到稳定治疗剂量的时间以及不良事件风险,包括全因死亡率、血栓栓塞事件、总出血和大出血。纳入了11项随机对照试验,共2639名参与者。我们的汇总估计表明,基于药物遗传学的给药算法并未提高处于治疗范围内的时间百分比[加权平均差,4.26;95%置信区间(CI),-0.50至9.01;P = 0.08],但它显著缩短了达到稳定治疗剂量的时间(加权平均差,-8.67;95% CI,-11.86至-5.49;P < 0.00001)。此外,基于药物遗传学的算法显著降低了大出血风险(比值比,0.48;95% CI,0.23至0.98;P = 0.04),但未降低全因死亡率、总出血或血栓栓塞事件的风险。我们的结果表明,基于药物遗传学的华法林给药算法显著提高了国际标准化比值校正的效率并降低了大出血风险。